Molecular pharmacology of selective Na <sub>v</sub> 1.6 and dual Na <sub>v</sub> 1.6 and Na <sub>v</sub> 1.2 channel inhibitors that suppress excitatory neuronal activity ex vivo
Samuel J. Goodchild(Xenon Pharmaceuticals (Canada)), J. P. Johnson(Xenon Pharmaceuticals (Canada)), Peter C. Ruben(Simon Fraser University), Thilo Focken(Xenon Pharmaceuticals (Canada)), Samrat Thouta(University of British Columbia), R. Ryley Parrish(Brigham Young University), Richard A. Dean(Xenon Pharmaceuticals (Canada)), Maegan Soriano(Xenon Pharmaceuticals (Canada)), Charles J. Cohen(Xenon Pharmaceuticals (Canada)), Aaron D. Williams(Xenon Pharmaceuticals (Canada)), Mohammad‐Reza Ghovanloo(Yale University), Noah Gregory Shuart(Xenon Pharmaceuticals (Canada)), Fiona Scott(Centre for Immunity, Infection and Evolution), Janette Mezeyova(Xenon Pharmaceuticals (Canada)), Wenlei Ye(Neurocrine Biosciences (United States)), James R. Empfield(Xenon Pharmaceuticals (Canada)), Matthew Waldbrook(Xenon Pharmaceuticals (Canada))
Cited by 1
Related Papers
Cortical DNA methylation maintains remote memory
|Nature Neuroscience|2010|518
Progress in Understanding and Treating SCN2A-Mediated Disorders
|Trends in Neurosciences|2018|339
Loss-of-Function and Gain-of-Function Mutations in KCNQ5 Cause Intellectual Disability or Epileptic Encephalopathy
|The American Journal of Human Genetics|2017|130